操 明, 呂彩霞, 董 璇, 嚴(yán)鳳琴, 尚莎莎, 吳曉芬, 王 冠, 阮 磊, 全小慶,張存泰
?
合并糖尿病的急性冠脈綜合征患者共刺激分子與炎癥指標(biāo)的研究
操 明, 呂彩霞, 董 璇, 嚴(yán)鳳琴, 尚莎莎, 吳曉芬, 王 冠, 阮 磊, 全小慶,張存泰*
(華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬同濟(jì)醫(yī)院綜合科, 武漢 430030)
探討CD4+CD28nullT淋巴細(xì)胞及炎癥因子C反應(yīng)蛋白(CRP)在合并糖尿病的冠心病患者發(fā)病機(jī)制中的作用。51例經(jīng)冠狀動(dòng)脈造影確認(rèn)為急性冠脈綜合征(ACS)的患者,根據(jù)1999年WHO標(biāo)準(zhǔn)分為2型糖尿病合并ACS組21例,單純ACS組30例,對(duì)所有研究對(duì)象均通過流式細(xì)胞術(shù)測(cè)量外周血中CD4+CD28nullT淋巴細(xì)胞的數(shù)量,對(duì)比分析兩組患者的臨床資料和冠狀動(dòng)脈造影結(jié)果。與單純ACS患者相比較,合并糖尿病的ACS患者外周血CD4+CD28nullT淋巴細(xì)胞的數(shù)量顯著增多[(4.66±4.24)%(8.89±6.45)%,<0.05],CRP濃度無明顯統(tǒng)計(jì)學(xué)差異[(1.97±1.05)(2.22±1.14)mg/L,>0.05],冠狀動(dòng)脈造影顯示完全閉塞、彌漫病變比例較高(711,<0.05;612,<0.01 )。糖尿病合并ACS患者冠狀動(dòng)脈病變累及范圍廣且程度重,共刺激分子可能與合并糖尿病的ACS患者的免疫調(diào)節(jié)異常有關(guān)。
糖尿病; 急性冠脈綜合征; T淋巴細(xì)胞; 炎癥
心血管疾病是糖尿病患者死亡的首要原因,糖尿病可顯著增加冠狀動(dòng)脈硬化、心肌梗死、死亡的發(fā)生率,其病理機(jī)制與內(nèi)皮功能紊亂、炎癥和免疫反應(yīng)改變有關(guān)[1,2]。CD4+CD28nullT淋巴細(xì)胞作為免疫系統(tǒng)功能退化的標(biāo)志之一,與許多炎癥反應(yīng)性疾病相關(guān)[3]。國(guó)內(nèi)外及我們課題組既往研究均證實(shí)CD4+CD28nullT淋巴細(xì)胞有促進(jìn)冠心病動(dòng)脈粥樣硬化生成與斑塊不穩(wěn)定的作用[4,5];此外,近年來亦有越來越多的研究表明糖尿病患者CD4+CD28nullT淋巴細(xì)胞較正常人群明顯增多。免疫系統(tǒng)的激活和慢性炎癥均參與了冠心病與2型糖尿病的發(fā)生與發(fā)展[6]。但是,目前尚無CD4+CD28nullT淋巴細(xì)胞在合并糖尿病的急性冠脈綜合征(acute coronary syndrome,ACS)患者中的相關(guān)研究。本研究以非糖尿病的ACS患者為對(duì)照組,觀察合并糖尿病的ACS患者外周血中CD4+CD28nullT淋巴細(xì)胞的數(shù)量、C反應(yīng)蛋白(C-reactive protein,CRP)濃度以及冠狀動(dòng)脈造影特點(diǎn),為ACS合并糖尿病患者的二級(jí)預(yù)防提供預(yù)測(cè)依據(jù)。
納入2010年3月至2011年6月華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬同濟(jì)醫(yī)院心內(nèi)科收治的ACS合并2型糖尿病的患者21例作為病例組(合并糖尿病的ACS組),其中男16例,女5例;同時(shí)入選單純ACS患者30例作為對(duì)照組(單純ACS組),其中男20例,女10例。ACS患者均符合中華醫(yī)學(xué)會(huì)心血管分會(huì)制定的急性心肌梗死和不穩(wěn)定心絞痛的診斷標(biāo)準(zhǔn);2型糖尿病均為確定有糖尿病病史并符合WHO1999年的糖尿病診斷標(biāo)準(zhǔn)。入選患者均排除:(1)合并嚴(yán)重感染、惡性腫瘤和免疫系統(tǒng)疾?。唬?)既往有經(jīng)皮冠狀動(dòng)脈介入或支架植入史;(3)正在服用抗炎藥物或他汀類藥物。
流式細(xì)胞儀(FACSCanto,美國(guó)Beckman Coulter);酶標(biāo)儀(美國(guó)Thermo Labsystem Multiskan MK3),單克隆抗體CD3-FITC、CD4-PerCP-Cy5.5、CD28-PE (美國(guó)eBioscience);紅細(xì)胞裂解液(谷歌生物公司),人CRP ELISA試劑盒(美國(guó)eBioscience)。
收集外周靜脈血10ml,3000r/min離心10min,留取上清血漿。采取密度梯度離心法分離外周血單個(gè)核細(xì)胞,將分離的細(xì)胞加入1640培養(yǎng)基置于培養(yǎng)箱中孵育過夜去除單核細(xì)胞,取細(xì)胞懸液洗滌后,將其濃度調(diào)整為106個(gè)/ml。采用ELISA試劑盒檢測(cè)血漿中CRP的濃度。
取50ul上述細(xì)胞懸液加入FITC標(biāo)記的CD3、PerCP-Cy5.5標(biāo)記的CD4和PE標(biāo)記的CD28流式抗體,置于6℃避光孵育20min后,用PBS洗滌細(xì)胞2次,再加入流式固定液重懸細(xì)胞,用流式細(xì)胞儀計(jì)數(shù)CD4+CD28nullT淋巴細(xì)胞占CD4+T細(xì)胞的比例。
單純ACS組與合并糖尿病的ACS組性別、年齡、吸煙史、血脂水平及左室射血分?jǐn)?shù)(left ventricular ejection fraction,LVEF)差異均無統(tǒng)計(jì)學(xué)意義(表1)。
與單純ACS患者相比,合并糖尿病的ACS患者外周血CD4+CD28nullT淋巴細(xì)胞比例顯著增多[(4.66±4.24)%(8.89±6.45)%,<0.05;圖1] 。
與單純ACS患者比較,合并糖尿病的ACS患者血漿CRP濃度差異無統(tǒng)計(jì)學(xué)意義;冠狀動(dòng)脈造影結(jié)果提示合并糖尿病的ACS患者冠狀動(dòng)脈彌漫性及閉塞性病變的比例均高于單純ACS患者(分別=0.033,=0.007;表2)。
表1單純ACS組和糖尿病合并ACS組患者之間臨床資料的比較
Table 1 Comparison of clinical information between ACS and DM-ACS patients
注: ACS: 急性冠脈綜合征; LDL-C: 低密度脂蛋白膽固醇; LVEF: 左室射血分?jǐn)?shù)
圖1 糖尿病合并ACS組外周血中CD4+CD28null T淋巴細(xì)胞的比例較單純ACS組顯著增高
Figure 1 The percentage of CD4+CD28nullT lymphocytes significantly increases in DM-ACS patients compared with that of the pure ACS patients
A: P2表示外周血中CD3+CD4+T淋巴細(xì)胞; B: Q4-1表示單純ACS患者外周血中CD4+CD28nullT淋巴細(xì)胞占CD3+CD4+T淋巴細(xì)胞的比例; C: Q4-1表示合并糖尿病的ACS患者外周血中CD4+CD28nullT淋巴細(xì)胞占CD3+CD4+T淋巴細(xì)胞的比例; D: 統(tǒng)計(jì)分析。與單純ACS組比較,*<0.05
表2兩組患者C反應(yīng)蛋白濃度及冠狀動(dòng)脈造影結(jié)果比較
Table 2 Comparison of C-reactive protein and angiography results between ACS and DM-ACS patients
注: ACS: 急性冠脈綜合征。與單純ACS組比較,*<0.05,**<0.01
CD4+CD28nullT淋巴細(xì)胞是一個(gè)具有特殊生物學(xué)效應(yīng)的細(xì)胞亞型,具有自然殺傷細(xì)胞毒性,已報(bào)道其與許多免疫相關(guān)性疾病密切相關(guān),包括冠心病和2型糖尿病。輔助性T細(xì)胞Th1和Th2通過分泌不同的細(xì)胞因子相互制約,維持機(jī)體免疫系統(tǒng)處于動(dòng)態(tài)平衡。由于缺乏共刺激分子CD28,CD4+CD28nullT淋巴細(xì)胞主要表現(xiàn)為分泌Th1型細(xì)胞因子的功能特性,通過大量分泌干擾素(interferons,IFN)-γ及腫瘤壞死因子(tumor necrosis factor,TNF)-α等,造成Th1與Th2細(xì)胞調(diào)節(jié)的不平衡,促成自身免疫疾病的發(fā)生與發(fā)展。2型糖尿病主要病理機(jī)制是胰島素抵抗,IFN-γ及TNF-α可通過升高游離脂肪酸水平影響胰島素信號(hào)轉(zhuǎn)導(dǎo)通路蛋白,降低組織器官對(duì)胰島素的敏感性,參與胰島素抵抗的發(fā)生[7,8]。冠心病作為糖尿病主要的血管并發(fā)癥,基本病理改變是動(dòng)脈粥樣硬化,已有研究發(fā)現(xiàn)CD4+CD28nullT淋巴細(xì)胞與急性冠狀動(dòng)脈病變密切相關(guān),在ACS患者粥樣硬化斑塊局部及外周血中均發(fā)現(xiàn)該細(xì)胞數(shù)量顯著增多[9]。CD4+CD28nullT淋巴細(xì)胞一方面通過分泌穿孔素和顆粒酶直接殺傷靶細(xì)胞,引起局部組織炎性病變;另一方面通過IFN-γ激活巨噬細(xì)胞,促進(jìn)泡沫細(xì)胞形成,導(dǎo)致動(dòng)脈粥樣硬化的發(fā)生[10]。
與非糖尿病患者相比較,合并糖尿病的冠心病患者冠狀動(dòng)脈粥樣硬化病變的程度更為嚴(yán)重,且有較嚴(yán)重的多支病變[11,12],而且行PCI和冠狀動(dòng)脈旁路移植術(shù)術(shù)后療效也明顯差于非糖尿病患者,因而糖尿病冠心病患者一級(jí)和二級(jí)預(yù)防對(duì)改善患者預(yù)后具有重要的臨床意義。本研究結(jié)果發(fā)現(xiàn)合并糖尿病的ACS患者較單純ACS患者外周血中CD4+CD28nullT淋巴細(xì)胞顯著增多,這表明CD4+CD28nullT淋巴細(xì)胞作為一個(gè)具有特殊生物學(xué)效應(yīng)的細(xì)胞亞群,參與了冠心病合并糖尿病時(shí)異常T細(xì)胞免疫反應(yīng)的病理過程,研究其生物學(xué)功能可為探討糖尿病及其血管并發(fā)癥的免疫病理機(jī)制提供新的思路,并為臨床治療與該疾病的一二級(jí)預(yù)防奠定理論基礎(chǔ)。
[1] Preis SR, Hwang SJ, Coady S,. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005[J]. Circulation, 2009, 119(13): 1728-1735.
[2] Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease[J]. J Am Coll Cardiol, 2009, 53(5 Suppl): S35-42.
[3] Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence[J]. Immunol Rev, 2005, 205: 158-169.
[4] Sun W, Zheng L, Huang L. Role of unusual CD4+CD28-T cells in acute coronary syndrome[J]. Mol Biol Rep, 2012, 39(3): 3337-3342.
[5] Xu R, Cao M, Wu X,. Kv1.3 channels as a potential target for immunomodulation of CD4+CD28nullT cells in patients with acute coronary syndrome[J]. Clin Immunol, 2012, 142(2): 209-217.
[6] Vrachnis N, Belitsos P, Sifakis S,. Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus[J]. Int J Endocrinol, 2012: 549748. Epub 2012 Apr 9.
[7] Wolf AM, Wolf D, Rumpold H,. The kinase inhibitor imatinib mesylate inhibits TNF-(alpha) productionand prevents TNF-dependent acute hepatic inflammation[J]. Proc Natl Acad Sci USA, 2005, 102(38): 13622-13627.
[8] Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation[J]. Hypertension, 2005, 45(5):828-833.
[9] Liuzzo G, Goronzy JJ, Yang H,. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes[J]. Circulation, 2000, 101(25): 2883-2888.
[10] Dumitriu IE, Araquas ET, Baboonian C,. CD4+CD28nullT cells in coronary artery disease: when helpers become killers[J]. Cardiovasc Res, 2009, 81(1): 11-19.
[11] Yan Q, Gu WQ, Hong J,. Coronary angiographic studies of impaired glucose regulation and coronary artery disease in Chinese nondiabetic subjects[J]. Endocrine, 2009, 36(3): 457-463.
[12] Kataoka Y, Yasuda S, Morii I,. Quantitative coronary angiographic studies of patients with angina pectoris and impaired glucose tolerance[J]. Diabetes Care, 2005, 28(9): 2217-2222.
(編輯: 王雪萍)
Costimulatory molecules and inflammatory indicator in diabetes and non-diabetes acute coronary syndrome patients
CAO Ming, LYU Caixia, DONG Xuan, YAN Fengqin, SHANG Shasha, WU Xiaofen, WANG Guan, RUAN Lei, QUAN Xiaoqing, ZHANG Cuntai*
(Department of Integrated Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China)
To determine the roles of the frequency of CD4+CD28nullT lymphocytes and the serum level of C-reactive protein (CRP) in diabetes and non-diabetes coronary patients.A total of 51 patients with acute coronary syndrome (ACS) in the Department of Cardiology from our hospital during March 2010 to June 2011 were enrolled in this study. They were further divided into diabetes (=21) and non-diabetes (=30) group, according to the diagnostic standards of type 2 diabetes mellitus. Frequency of CD4+CD28nullT lymphocytes was analyzed by multiple-color flow cytometry, and serum level of CRP was measured by ELISA. Their clinical data and results of coronary arteriography were recorded and analyzed.Compared to the non-diabetes ACS patients, the frequency of CD4+CD28nullT lymphocytes was higher in peripheral blood of diabetes ACS patients [(4.66±4.24)%(8.89±6.45)%,<0.05]. But there was no significant difference in serum level of CRP between the two groups [(1.97±1.05)(2.22±1.14)mg/L,>0.05]. Coronary angiography suggested that the rate of complete obstruction and diffuse pathogenic changes were more severe in diabetes ACS patients (711,<0.05; 612,<0.01).Coronary pathogenic changes are more severe in diabetes ACS patients than those without diabetes. Costimulatory molecule may be involved in the immune-modulation disturbance of patients with diabetes and ACS.
diabetes mellitus; acute coronary syndrome; T lymphocyte; inflammation
(No. 30871070)(No. 20604002-258)
R543.3
A
10.3724/SP.J.1264.2013.00033
2012-10-23;
2012-11-31
國(guó)家自然科學(xué)基金(No. 30871070); 湖北省自然科學(xué)基金(No. 20604002-258)
張存泰, Tel: 027-83663050, E-mail: ctzhang0425@163.com